GDRXNasdaqServices-Computer Processing & Data PreparationFiscal year ends December 31
GoodRx Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.37+0.01 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- 84.3
- Dividend yield
- –
GoodRx Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Prescription transactions revenue | $544.00M | $577.55M | $550.74M | $550.54M | $593.36M | $488.26M | $364.58M | $242.91M | 68.3% | -5.8% |
| Pharma manufacturer solutions revenue | $151.38M | $107.24M | $85.07M | – | – | – | – | – | 19.0% | +41.2% |
| Subscription revenue | $83.79M | $86.54M | $94.41M | $96.17M | $59.93M | $29.39M | $13.09M | – | 10.5% | -3.2% |
| Other revenue | $17.69M | $21.00M | $20.05M | $20.43M | $18.79M | $12.57M | $10.56M | $6.61M | 2.2% | -15.8% |
| Pharma Direct revenue | – | $107.24M | $85.07M | $99.43M | $73.35M | $20.49M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of GoodRx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.